Inflammatory Bowel Diseases - ECAB
- Philip Augustine, MD, DM, Medical Director and Director, Digestive Diseases Centre, Lakeshore Hospital & Research Centre Ltd., Kochi, Kerala.
GI tuberculosis is often suspected on the basis of its clinical, radiological, and endoscopic features, but histological or microbiologic proof of the disease is often difficult to achieve. Therefore, the majority of patients are treated with antitubercular drugs on presumptive diagnosis only. Similar clinical, endoscopic, radiological, and histological features of GI tuberculosis and Crohnâs disease pose a serious challenge to the treating physician. The rate of misdiagnosis of these conditions using conventional diagnostic measures has been reported to be around 50-70%. Thus differentiation and diagnosis of these conditions is difficult but very important for correct treatment of the patients. Recently some serological tests have come up for diagnosing Crohnâs disease and ulcerative colitis, which may help to distinguish these disorders from each other and from GI tuberculosis.
Besides diagnosis, treatment for IBD is also an emerging field in which active research is going on. The traditional drugs used in treatment of IBD include steroids and aminosalicylates. Recent studies have evaluated the role of azathioprine, methotrexate, and cyclosporine. Apart from improving efficacy of therapy in short term, these agents have raised debate on complications of therapy, long-term efficacy, and cost. Management of IBD during pregnancy and fistulising Crohnâs disease are other areas of concern.
- Published: July 2012
- Imprint: ELSEVIER
- ISBN: 978-81-312-3191-3
Table of Contents
Diagnosis of Inflammatory Bowel Disease
Differentiation of Crohnâs Disease from Intestinal Tuberculosis
Emerging Therapies in Inflammatory Bowel Disease
Genetics of Inflammatory Bowel Disease
Other Books in This Series